콘텐츠로 이동

프로게스토겐 개요

Progestogens remain one of the most fiercely debated topics in transgender female HRT. Unlike estrogen and anti-androgens, progestogens are not a mandatory component of feminizing hormone therapy. The major international clinical guidelines maintain a highly cautious stance regarding their widespread use [1] [2] .


  • Breast Volume/Shape: Research by Prior (2019) suggests that introducing progesterone later in HRT might improve the subjective “roundness” and fullness of breast development by maturing the lobuloalveolar tissue [5] . However, this study relied on patients’ self-reported satisfaction and did not include objective measurements of breast volume.
  • Sleep Improvement: Micronized progesterone possesses a heavy sedative effect. For transgender women suffering from insomnia, taking it before bed drastically improves sleep architecture [5] .
  • Mood Stabilization: Many users report that progesterone levels out their emotional volatility, though rigorous controlled studies backing this specific to transgender women are currently lacking.
  • The Endocrine Society 2017 Guidelines explicitly state there is insufficient clinical evidence to warrant the routine prescription of progestogens in transgender HRT [1] .
  • WPATH SOC 8 maintains the same highly cautious stance, refusing to list it as a standard requirement [2] .
  • Synthetic progestins (including the progestogenic effect of high-dose CPA) are definitively linked to heightened breast cancer and VTE risks [4] .
  • There are still exactly zero high-quality Randomized Controlled Trials (RCTs) proving that progesterone organically increases breast cup size in trans women.

FeatureBioidentical Micronized ProgesteroneSynthetic Progestins (MPA, etc.)
Common Brands Prometrium, Utrogestan Provera (MPA), NETA, Levonorgestrel
Chemical Structure Identical to human biological progesterone Chemically altered; metabolizes differently
VTE Risk Early data suggests far lower risk than synthetics Significantly increases blood clot risks
Breast Cancer Risk Short-term data implies lower risk WHI study proved severe risk increase
Sedative Effect Heavy (Excellent for sleep aid) None, or acts completely differently
Recommendation The ONLY acceptable option if choosing to use a progestogen NEVER use for transgender HRT

Preliminary evidence indicates that bioidentical micronized progesterone carries a distinctly lower VTE (clot) risk compared to synthetics [6] . This makes it infinitely superior.


If, after understanding the massive gaps in clinical data, you still wish to trial progesterone, follow these rigid safety rules:

  1. Wait at least 12 months: Let estrogen build the ductal branches first. Do not ruin your potential by rushing. Wait until Tanner Stage III [3] .
  2. Accept only Bioidentical: Demand Micronized Progesterone (Prometrium/Utrogestan).
  3. Start Low: Begin at 100 mg/day, taken immediately before bed.
  4. Monitor Everything: Assess your mood, breast tenderness, and sleep quality 4 to 8 weeks after starting.
  5. More is not Better: If 100mg does nothing, jumping to 400mg isn’t going to magically force breast growth.

References

  1. Hembree WC et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons. J Clin Endocrinol Metab 2017;102(11):3869-3903. DOI:10.1210/jc.2017-01658
  2. Coleman E et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022;23(S1):S1-S259. DOI:10.1080/26895269.2022.2100644
  3. Patel et al. Breast Development in Transgender Women on Hormone Therapy. 2021. PMC8664122
  4. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019.
  5. Prior JC. Progesterone is important for transgender women’s therapy — applying evidence for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab 2019;104(4):1181-1186. DOI:10.1210/jc.2018-01777
  6. Canonico M et al. Hormone therapy and venous thromboembolism: an updated overview. Climacteric 2018.